+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Rituxan"

Cancer Monoclonal Antibodies Global Market Report 2024 - Product Thumbnail Image

Cancer Monoclonal Antibodies Global Market Report 2024

  • Report
  • February 2024
  • 250 Pages
  • Global
From
Arthritis Monoclonal Antibodies Global Market Report 2024 - Product Thumbnail Image

Arthritis Monoclonal Antibodies Global Market Report 2024

  • Report
  • February 2024
  • 250 Pages
  • Global
From
From
Lymphoma Therapeutics: Global Strategic Business Report - Product Thumbnail Image

Lymphoma Therapeutics: Global Strategic Business Report

  • Report
  • May 2024
  • 406 Pages
  • Global
From
From
Central Nervous System Lymphoma - Pipeline Insight, 2024 - Product Thumbnail Image

Central Nervous System Lymphoma - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 40 Pages
  • Global
From
From
From
From
From
From
From
From
From
From
RITUXAN Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

RITUXAN Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • January 2023
  • 30 Pages
  • Global
From
Loading Indicator

Rituxan (rituximab) is a monoclonal antibody used to treat a variety of immune disorders, including non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and granulomatosis with polyangiitis. It is used in combination with other drugs to treat these conditions. Rituxan works by targeting and destroying B-cells, which are a type of white blood cell involved in the body's immune response. Rituxan is a biologic drug, meaning it is made from living cells. It is administered intravenously and is typically given in two doses, two weeks apart. The drug has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of certain immune disorders. Rituxan is a widely used drug in the immune disorders market. It is one of the most prescribed drugs for the treatment of non-Hodgkin's lymphoma and rheumatoid arthritis. It is also used off-label to treat other conditions, such as systemic lupus erythematosus. Some companies in the Rituxan market include Genentech, Biogen, and Roche. Show Less Read more